ETFIQData as of Nov 18, 2026. · etfiq.com/funds/xph

XPH Fact Sheet: State Street SPDR S&P Pharmaceuticals ETF

Share
$64.23
close, Nov 18, 2026

Over the year to Nov 18, 2026, XPH returned +23.8% in total and charged 0.35% a year.

1-year total return
+23.8%
to Nov 18, 2026
Expense ratio
0.35%
a year
Net assets
$508m
on Nov 17, 2026
Net flow, last 5 trading days
+$20.6m
daily basis to Nov 17, 2026

Growth of $10,000, 1 year

XPH $12,377 +23.8% · IVV $11,186 +11.9% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.

Returns

WindowTotal return
1 month+3.2%
3 months−13.2%
Year to date+15.0%
1 year+23.8%
3 years+81.2%
5 years+42.0%

Total return, distributions reinvested, each window to Nov 18, 2026.

Ten largest positions

HoldingWeight
XERIS BIOPHARMA HOLDINGS INC4.62%
VERADERMICS INC2.67%
ELI LILLY + CO2.67%
PACIRA BIOSCIENCES INC2.64%
VIATRIS INC2.63%
AMNEAL PHARMACEUTICALS INC2.60%
MAZE THERAPEUTICS INC2.52%
ZOETIS INC2.41%
ROYALTY PHARMA PLC CL A2.40%
PERRIGO CO PLC2.33%

XPH top ten by weight, 27.5% of the fund, of its 61 equity positions, from the holdings published by its issuer for Nov 17, 2026.

Facts

Equity fund · Tracks the S&P Pharmaceuticals Select Industry Index · First traded Jun 22, 2006 · Benchmark Its own holdings, as of Nov 17, 2026

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, XPH Fact Sheet: State Street SPDR S&P Pharmaceuticals ETF. Data as of Nov 18, 2026. https://etfiq.com/funds/xph/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/xph.